GLD Acquires Seelos Therapeutics’ Assets, Strengthening GLD’s Growing Life Sciences Portfolio
GLD Announces Successful Closing of Seelos Assets; Includes Ketamine and Trehalose Programs Advancing into Phase 3 Clinical Trials
Read More
GLD Launches New Biotech Company, Altagenics, to Accelerate Drug Discovery for Muscle-Wasting Diseases
In collaboration with Heligenics GigaAssay™ platform, the companies will speed the development of new therapies in aging-related diseases.
Read More